1.4.2 Continuation of Study Drug Treatment Following Radiographic Disease 
1.4.6 Rationale for Genotyping and Assessment of Biomarkers in Archived Tumor 
10.2 Procedures for Recording and Reporting Adverse Events and Serious Adverse 
15.1 Radiographic Disease Assessment According to Prostate Cancer Clinical Trials 
1. The BPI SF worst pain score is 4 with a 2 point increase over baseline 
2. The BPI SF worst pain score is 4 but not less than baseline with new or 
3. The BPI SF worst pain score is 3 but not less than baseline with new or 
1. BACKGROUND AND STUDY RATIONALE
1.1 Scientific Background
1.2 Nonclinical Experience With Orteronel
1.4 Study Rationale
1.4.1 Dose Selection
1.4.2 Continuation of Study Drug Treatment Following Radiographic Disease 
1.4.3 The Role of Prednisone
1.4.4 Concomitant Therapy Selection
1.4.5 Circulating Tumor Cells (CTCs)
1.4.6 Rationale for Genotyping and Assessment of Biomarkers in Archived Tumor 
1.5 Risks and Benefits
1.5.1 Potential Benefits 
1.5.2 Identified Risks
1.5.3 Potential Risks 
2. STUDY OBJECTIVES
2.1 Primary Objective
2.2 Key Secondary Objectives
2.3 Other Secondary Objectives
2.4 Exploratory Objectives
3. STUDY ENDPOINTS
3.1 Primary Endpoint
3.2 Key Secondary Endpoints
3.3 Other Secondary Endpoints
3.4 Exploratory Endpoints
4. STUDY DESIGN
4.1 Overview of Study Design
4.2 Number of Patients
4.3 Duration of Study
5. STUDY POPULATION
5.1 Inclusion Criteria
8. Must have received prior docetaxel therapy:
9. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 (see 
10. Screening clinical laboratory values as specified below:
5.2 Exclusion Criteria
4. Exposure to radioisotope therapy within 4 weeks of receiving the first dose of study 
6. Treatment with any investigational compound within 30 days prior to the first dose 
8. Diagnosis of or treatment for another systemic malignancy within 2 years before the 
11. ECG abnormalities of:
12. Uncontrolled hypertension despite appropriate medical therapy (blood pressure BP 
14. Likely inability to comply with the protocol or cooperate fully with the investigator 
17. Those patients whose prostate cancer is confined to just the prostate bed or 
5.3 Criteria for Patients Crossing Over to Orteronel Treatment
3. Screening clinical laboratory values as specified below (screening labs for patients 
6. No likely inability to comply with the protocol or cooperate fully with the 
6. STUDY DRUG
6.1 Test Article
6.1.2 Gonadotropin Releasing Hormone Analogue and Prednisone Supply
6.2 Study Drug Administration
6.3 Dose Modification and Supportive Care Guidelines
6.3.1 Dose Levels for Study Drug
6.3.1.1 Dose Modifications
6.3.1.2 Criteria for Study Drug Initial Dose Reduction
6.3.1.3 Criteria for Study Drug Dose Re escalation
6.3.1.3.1 Re escalation for Grade 2 Intolerable Adverse Events
6.3.1.3.2 Re escalation of Study Drug Following a Grade 3 or 4 Adverse Event
6.3.1.4 Criteria for Discontinuation of Study Drug
6.3.2 Specific Guidelines for Possible Study Drug Related Toxicities
6.4 Excluded Concomitant Medications and Procedures
6.5 Permitted Concomitant Medications and Procedures 
6.6 Precautions and Restrictions
6.7 Management of Overdose
6.8 Blinding and Unblinding
6.9 Description of Investigational Agents
6.11 Packaging and Labeling
7. STUDY CONDUCT
7.1 Study Personnel and Organizations
7.2 Arrangements for Recruitment of Patients
7.3 Treatment Group Assignments
7.4 Study Procedures
7.4.1 Informed Consent
7.4.2 Patient Demographics
7.4.3 Medical History
7.4.4 Physical Examination
7.4.5 Patient Height and Weight
7.4.6 Vital Signs
7.4.7 Concomitant Medications and Procedures
7.4.8 Adverse Events
7.4.9 Cardiac Assessments
7.4.10 ECOG Performance Status
7.4.11 Clinical Laboratory Evaluations
7.4.12 Serology
7.4.13 Disease Assessment
7.4.14 Tumor Specimen Measurements
7.4.15 Circulating Tumor Cells
7.4.16 Whole Blood Sample for Germline DNA 
7.4.17 Pharmacokinetic Measurements
7.4.18 Pain Assessment
1. The BPI SF worst pain score is 4 with a 2 point increase over baseline in BPI 
2. The BPI SF worst pain score is 4 but not less than baseline with new or increased 
3. The BPI SF worst pain score is 3 but not less than baseline with new or increased 
7.4.19 Quality of Life Assessment
7.4.20 Utility Measurement
7.4.21 Medical Resource Utilization Data Collection
7.4.22 Cost Assessment
7.4.23 Unscheduled Visits
7.4.24 Long Term Survival Status
7.5 Completion of Treatment
7.6 Completion of Study
7.7 Discontinuation of Treatment With Study Drug and Patient Replacement
7.8 Withdrawal of Patients From Study
7.9 Study Compliance
8. STATISTICAL AND QUANTITATIVE ANALYSES
8.1 Statistical Methods
8.1.1 Determination of Sample Size
8.1.2 Randomization and Stratification
8.1.3 Populations for Analysis
8.1.5 Demographic and Baseline Characteristics
8.1.6 Efficacy Analyses
8.1.6.1 General Methodology
8.1.6.2 Analysis of Primary Efficacy Endpoint
8.1.6.3 Analyses of Key Secondary Endpoints
8.1.6.4 Analyses of Other Secondary Endpoints
8.1.7 Safety Analysis
8.1.8 Analyses of Patient Reported Outcomes
8.1.9 Interim Analyses
8.1.10 Other Exploratory Analyses
8.2 Population Pharmacokinetic Modeling
9. STUDY COMMITTEES
9.1 Independent Data Monitoring Committee
10. ADVERSE EVENTS
10.1 Definitions
10.1.2 Serious Adverse Event Definition
10.1.3 Pretreatment Event Definition
10.2 Procedures for Recording and Reporting Adverse Events and Serious Adverse 
10.3 Reporting of Suspected Unexpected Serious Adverse Reactions
10.4 Monitoring of Adverse Events and Period of Observation
10.5 Procedures for Reporting Drug Exposure During Pregnancy and Birth Events
11. ADMINISTRATIVE REQUIREMENTS
11.1 Good Clinical Practice
11.2 Data Quality Assurance
11.3 Electronic Case Report Form Completion 
11.4 Study Monitoring
11.5 Ethical Considerations
11.6 Patient Information and Informed Consent
11.7 Patient Confidentiality
11.8 Investigator Compliance
11.9 On site Audits
11.10 Investigator and Site Responsibility for Drug Accountability
11.11 Product Complaints 
11.12 Closure of the Study
11.13 Record Retention
12. USE OF INFORMATION
13. INVESTIGATOR AGREEMENT
14. REFERENCES
24. Confidential
71. Confidential
83. Confidential
95. Confidential
15. APPENDICES
15.1 Radiographic Disease Assessment According to Prostate Cancer Clinical 
15.1.1 Recording Baseline Assessments
15.1.1.1 Soft Tissue Lesion Assessment
15.1.1.2 Soft Tissue Assessments Following Baseline
15.1.2 Response Definitions for RECIST Evaluable Soft Tissue Lesions
15.1.2.1 Definition of Complete Response
15.1.2.2 Definition of Partial Response
15.1.2.3 Definition of Stable Disease
15.1.2.4 Definition of Soft Tissue Progression
15.1.2.4.1 Assessment of Soft Tissue Time Point Response
15.1.3 Radionuclide Bone Scan Assessment 
15.1.3.1 Baseline Assessment
15.1.3.2 Postbaseline Assessments and Definition of Progression of Bone Metastatic 
15.1.4 Overall Response Assessment
15.2 World Health Organization Steps of Analgesics and OME Conversions
15.2.1 World Health Organization Steps of Analgesics
15.2.2 Oral Morphine Equivalent (OME) Conversions
30 b
15.3 Eastern Cooperative Oncology Group Scale for Performance Status
15.4 Cockcroft Gault Formula
15.5 New York Heart Association Classification of Cardiac Disease
15.6 Specific Guidelines for Possible Study Drug Related Toxicities
15.6.1 Fatigue
15.6.2 Gastrointestinal Adverse Events
15.6.3 Hypertension
15.6.5 Hyperglycemia
15.6.6 Renal Disorders
15.6.7 Suspected or Possible Adrenal Insufficiency
15.7 Schedule of Events for Patients Receiving Blinded Study Drug 
13 d 
13 d
13 d
13 d
13 d
15.8 Rationale and Purposes for Amendment 1
15.9 Rationale and Purposes for Amendment 2
15.10 Rationale and Purposes for Amendment 3
15.11 Rationale and Purposes for Amendment 4
15.12 Rationale and Purposes for Amendment 5
15.13 Rationale and Purposes for Amendment 6
15.14 Rationale and Purposes for Amendment 7
15.15 Rationale and Purposes for Amendment 8
15.16 Amendment 9 Detailed Summary of Changes
3. Screening clinical laboratory values as specified below (screening 
6. No likely inability to comply with the protocol or cooperate fully 
